{"nct_id":"NCT02179671","title":"Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","status":"COMPLETED","status_verified_date":"2019-08","start_date":"2014-07-25","start_date_type":"ACTUAL","primary_completion_date":"2016-06-11","primary_completion_date_type":"ACTUAL","completion_date":"2016-06-11","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["AZN"]}